Get started
Author

J. Lourenco

Observed names: J Lourenco, Jérémie Lourenco
ORCID: 0000-0001-9793-4501
Observed ORCID: 0000-0001-9793-4501
OpenAlex ID: A5031685859
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting
2021 · Colin Deschanvres, Jacques Reynes, et al. · Journal of Antimicrobial Chemotherapy · 15
Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)
2022 · Fabienne Marcellin, Sylvie Brégigeon-Ronot, et al. · JHEP Reports · 12
Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)
2020 · Fabienne Marcellin, Vincent Di Beo, et al. · Journal of Hepatology · 8
PDF
Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance
2023 · Sidonie Lambert-Niclot, Basma Abdi, et al. · Journal of Antimicrobial Chemotherapy · 5
HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data)
2022 · Tangui Barré, Patrick Mercié, et al. · AIDS Research and Therapy · 3
PDF
Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance
2025 · Alain Makinson, Firouze Bani-Sadr, et al. · Clinical Infectious Diseases · 1
Works count: 6
Citation count: 44
H-index: 4
I10-index: 2
Year
Topic
Type